In the treatment of chronic myeloid leukemia (CML), resistance to BCR‐ABL inhibitors makes it difficult to continue treatment and is directly related to life expectancy. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.